
BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy
Keywords: BCL2; DNA double strand break repair; Nonhomologous end-joining; KU; Prostate cancer; PARP inhibition; Radiosensitization;